Eli Lilly’s diabetes drug gets UK green light
Eli Lilly's diabetes drug Mounjaro has gained the approval of Britain's healthcare cost-effectiveness watchdog. IG financial analyst @Angeline Ong looks at why this is significant, post-Covid.
(Video Transcript)
Type 2 diabetes patients could benefit
Eli Lilly's diabetes drug Mounjaro is in focus as it gained the backing of Britain's health care cost effectiveness watchdog which said it would be a good option for patients with poorly controlled type 2 diabetes.
Now this is a really interesting space for drug makers and has been in focus in recent months because any drug related to obesity or diabetes and heart problems is seen as the new sort of revenue generators for these big pharma firms, of, course after the Covid revenue stream peters off.
Drug may soon be available from NHS
What's also interesting about this drug that is being marketed by Eli Lilly is that it has the potential to treat obesity. Now some 180,000 people could benefit from this new treatment in the UK and Diabetes UK alone estimates that more than five million people in the UK are living with diabetes.
So what's the next key date to look out for? Well, final guidance which is scheduled to be published on 11 October might mean we'll find out whether or not this drug will be made available in the UK's National Health Service within 90 days after that.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
